NEW YORK (GenomeWeb News) – Nanosphere today said that the US Food and Drug Administration has granted 510(k) clearance for the firm's Clostridium difficile molecular test.

The test, which runs on Nanosphere's Verigene system, detects the toxin A and B gene sequences of C. difficile and identifies the PCR ribotype 027 strain, which is associated with increased severity of disease. The test automates the steps of bacterial DNA extraction, amplification, hybridization, and target detection on the Verigene system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.